Abstract Library

#2122 Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?

Introduction: Quality of life (QoL) is important to all cancer patients. The EORTC QLQ-QNET21 is the most commonly used questionnaire in patients with neuroendocrine tumors (NETs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van Leeuwaarde R

Authors: Van Leeuwaarde R, Spada F, Cheung W, Gonzalez-Clavijo A, Pracht M,

Keywords: Quality of life, GEP-NET, EORTC QLQ-GINET21,

#1899 Sequence of Therapy and Survival among Advanced Pancreatic Neuroendocrine Tumors (pNETs)

Introduction: Therapy for advanced pNETs involves surgery (SG) and non-SG options, including liver ablation (ABL), systemic therapy (ST), somatostatin analogues (SSA). Optimal initial therapy is unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Tsang E, Speers C, Cheung W, Kennecke H,

Keywords: pNET, sequential therapy,

#1350 Understanding a Neuroendocrine Tumors’ Impact on Health Systems: A Population-Based Economic Analysis of Patterns of Costs

Introduction: Little is known on resource utilization and health care costs in NET care.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Hallet J

Authors: Hallet J, Law C, Cheung M, Fischer H, Liu N,

Keywords: costs, care patterns,

#941 Comparison of Radiolableled Somatostatin Analogues and (131) I-MIBG Treatment for the Management of Patients with Metastatic/Progressive Phaeochromocytomas and Paragangliomas

Introduction: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGGs) and pheochromocytomas (PCCs). To date, there is no study comparing (131)I-MIBG and peptide receptor radionuclide treatment (PRRT) in those patients.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Nastos K, Toumpanakis C, Cheung V, Navalkissoor S, Quigley A,

Keywords: paraganglioma, pheochromocytoma, (131)I-MIBG, PRRT,

#909 Association between Dose of Octreotide and Tumor Control in Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Gastroenteropancreatic neuroendocrine tumors (NETs) represent a heterogeneous group of tumors. Octreotide is used in the symptom control of NETs. The PROMID study demonstrated a benefit of octreotide on disease stabilization in midgut NETs, but a survival analysis was not possible due to insufficient events.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Lau S, Cheung W,

Keywords: GI, NET, octreotide,